[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Asmaa Hassan mohamed Abdel Mawjoud\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100631961","tnfaip3-gene-expression-in-ankylosing-spondylitis-and-psoriatic-arthritis-patients-and-its-relation-to-disease-activity-100631961",false,"NCT07507487","TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity","Inclusion Criteria:\n\n\\- 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984.\n\n2\\. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010)\n\nExclusion Criteria:\n\n* Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.",true,"ALL","18 Years","60 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients.\n2. Detect relation between TNFAIP3 and disease activity.\n\nInclusion criteria:\n\n1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10).\n2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11).\n\n   b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.",[27],"Ankylosing Spondylitis and Psoriatic Arthritis Patients","NOT_YET_RECRUITING","2026-03-27",{"date":31,"type":32},"2026-04-02","ACTUAL",{"date":34,"type":21},"2026-04",{"date":36,"type":21},"2029-07",{"name":38,"class":39},"Asmaa Hassan mohamed Abdel Mawjoud","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":5},"100404483","aberrant-expression-of-cd56-in-patients-with-hematologic-malignancies-100404483","NCT04546945","Aberrant Expression of CD56 in Patients With Hematologic Malignancies.","Resident Doctor at Clinical Pathology Department","Inclusion Criteria:\n\n* Patients with hematologic malignancies.\n* Newly diagnosed\n\nExclusion Criteria:\n\n* Patients with hematologic disorders other than hematologic malignancies.",{"count":48,"type":21},38,"12 Months","OBSERVATIONAL","CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.",[53],"Hematologic Malignancies","RECRUITING","2026-03-17",{"date":57,"type":32},"2026-03-18",{"date":59,"type":21},"2027-03-20",{"date":61,"type":21},"2027-12-30",{"name":38,"class":39},""]